U.S. Media Stock News

Event context and recent share performance Viper Energy (VNOM) has drawn investor attention after a year in which the stock showed a 21.3% total return decline, alongside shorter term moves over the past week, month, and past 3 months. With the shares last closing at US$37.28, and recent annual revenue of US$1.13b and net income of US$244.25m, many investors are rechecking how this royalty focused oil and gas name fits into their broader energy exposure. See our latest analysis for Viper...

Ciena recently highlighted continued benefits from rising network traffic, cloud adoption and bandwidth demand, supported by a robust outlook, a US$5.00 billion backlog and the 2025 acquisition of Nubis to bolster high-performance, low-power interconnects for AI workloads. An interesting angle is how Ciena’s mix of AI-focused interconnect technology and cost-control efforts could reshape its role in future data center infrastructure. We’ll now examine how Ciena’s AI-focused Nubis acquisition...

CrowdStrike Holdings (NasdaqGS:CRWD) is acquiring SGNL and Seraphic Security to expand its identity security and browser protection capabilities. The company is growing its Global Data Sovereignty initiative with new in country cloud deployments in Saudi Arabia, India, and the UAE. CrowdStrike has launched a partnership with Nord Security to bring AI powered cybersecurity tools to small and midsize businesses. CrowdStrike builds cloud based cybersecurity tools that help customers protect...

If you are wondering whether Incyte's recent share price puts it at a bargain or a stretch, this article walks through what the numbers are currently saying about value. Incyte's stock closed at US$102.62, with a 39.7% return over the last year and 22.7% over three years, while short term moves have been muted with a 0.8% decline over 7 days, a 0.1% decline over 30 days, and a 1.2% return year to date. Recent attention on Incyte has centered on how its product portfolio and pipeline updates...

In January 2026, Citigroup reported higher full-year net interest income and net income for 2025, while continuing sizable share repurchases totaling about US$14.35 billion and issuing multiple new callable senior and subordinated notes across various maturities. Alongside these capital actions, management signaled that its multi-year transformation is more than 80% complete and reaffirmed confidence in U.S. economic resilience, framing Citi’s balance sheet reshaping as part of a broader...

If you are wondering whether IDEAYA Biosciences' current share price fairly reflects its potential, this article will walk through what the numbers are actually saying about value. The stock last closed at US$35.75, with returns of 1.9% over 7 days, 6.6% over 30 days, 5.6% year to date, 54.4% over 1 year, 111.8% over 3 years and 103.0% over 5 years, which will naturally have some investors reassessing the balance between opportunity and risk. Recent news coverage has focused on IDEAYA...

On Holding (ONON) drew fresh attention after Goldman Sachs upgraded the stock, citing recent holiday demand, strength in China sales, and the potential for margin improvement as key supports for renewed investor interest. See our latest analysis for On Holding. Even with the Goldman Sachs upgrade, recent trading has been choppy, with a 1-month share price return of 9.16% and a 7-day share price return of a 6.64% decline. The 3-year total shareholder return of 102.48% contrasts sharply with...

Why tariffs and competition are suddenly in focus for Trade Desk investors Trade Desk (TTD) is back on investors’ radar after President Trump threatened a 10% tariff on European goods, a move that could pressure ad budgets for export heavy clients using its platform. See our latest analysis for Trade Desk. Those tariff headlines have hit just as Trade Desk contends with Kokai transition growing pains and tougher competition from Amazon, with the share price at $34.15 and a 1 year total...

McEwen (MUX) has put its Grey Fox Project in Timmins, Ontario in focus after reporting its year-end 2025 mineral resource estimate, featuring 1.9 million Indicated and 436,000 Inferred gold ounces. See our latest analysis for McEwen. The Grey Fox update comes after a busy start to 2026, including final drill results at the newly acquired Tartan Mine Project in Manitoba. It lands at a time when McEwen’s share price has gained 7.27% over one day, 26.56% over 30 days, and 31.10% year to date,...

If you are wondering whether Open Text is attractively priced today, the recent share moves and current valuation score give you a lot to work with. The stock closed at US$28.80, with a 13.0% decline over the last 7 days and a 13.7% decline over the last 30 days, while the 1 year return stands at 5.3% and the 5 year return at 29.3% decline. These price moves sit against a backdrop of ongoing attention on large software providers and their ability to keep delivering reliable cash flows and...

BXP has completed more than $1.0b of property sales, including residential, land, and non core office assets. The transactions occurred across several key gateway markets as part of a multi year portfolio optimization plan. These sales contribute to BXP's progress toward its $1.9b asset disposition target for 2025 to 2027. For investors watching NYSE:BXP, the latest $1.0b plus in completed property sales comes at a time when the stock trades around $65.63. Recent share performance has been...

Eastman Chemical: Recent Returns and Business Snapshot With no single headline event driving attention today, Eastman Chemical (EMN) is drawing interest as investors weigh its mixed share performance over the past year against current financial metrics and business fundamentals. The stock shows a 1 day return of about 3.6% decline and a 7 day return of about 2.8% decline, while the month return is about 4.1% and the past 3 months return is about 8.2%. Year to date, the stock return is about...

Parker-Hannifin (NYSE:PH) has agreed to acquire Filtration Group to expand its filtration and aftermarket footprint. The deal will be funded with a mix of new debt and cash, reflecting a commitment to building recurring revenue streams. The acquisition focuses on replacement parts and aftermarket demand, an area that can support more stable, repeat business. Parker-Hannifin enters this transaction with its shares at $929.49, after a 38.3% return over the past year and a very large return...

Wondering whether Intellia Therapeutics at US$12.83 is offering value or just another volatile biotech story? This article walks through what the current price really implies. The stock has returned 9.3% over the last 7 days, 39.0% over the past month, 39.3% year to date and 29.1% over the past year, while the 3 year and 5 year returns of 66.7% and 80.0% declines highlight how sharp previous pullbacks have been. These moves sit against a backdrop of ongoing interest in gene editing companies...

If you are wondering whether Toast at around US$32.76 is priced for its potential or already running ahead of itself, you are not alone. The stock is down 5.9% over the last week, 9.6% over the last month, 3.7% year to date, and 15.2% over the last year, although its 3 year return sits at 52.7%. These moves have kept Toast on many investors' watchlists as the market reassesses what it is willing to pay for high growth, software driven businesses. In that context, valuation tools and checks...

D.R. Horton (DHI) opened fiscal Q1 2026 with revenue of US$6.9b and basic EPS of US$2.03, putting a fresh quarterly snapshot alongside a trailing twelve month EPS of US$11.07 on revenue of US$33.5b and net income of US$3.3b. Over the past year, the company has seen quarterly revenue range from US$7.6b to US$10.0b and basic EPS move between US$2.03 and US$3.95, giving investors a clear view of how the current print sits within recent trading conditions and setting the stage for a closer look...

If you are wondering whether Blue Bird's current share price still offers value, the key question is how the market is weighing its recent performance against what the business could justify over time. The stock last closed at US$49.08, with returns of 0.3% over the past week, a 5.1% decline over 30 days, a 5.0% gain year to date and 16.7% over the last year, plus a very large return over three years and a 127.4% gain over five years. Recent headlines around Blue Bird have focused on the...

In January 2026, AOP Health US announced broader U.S. distribution of its critical care beta-blocker Rapiblyk through McKesson, Cardinal, Cencora Specialty Distribution, and M&D Specialty Distribution, while the Centers for Medicare & Medicaid Services again recognized McKesson as a Qualified Clinical Data Registry supporting oncology practices. CMS’s decision to retain McKesson’s oncology quality measures in the 2026 Advancing Cancer Care MIPS Value Pathways underscores the company’s...

Bank of America recently upgraded its view on Corning (NYSE:GLW), citing expectations around Apple's anticipated foldable device launch. The upgrade reflects potential demand for Corning technology in foldable displays and cover materials linked to that product cycle. Analysts are also flagging strong interest in AI related products across Corning's Optical, Solar, and Specialty segments. These factors come alongside strong recent financial results that are drawing fresh attention to...

Why Buckle’s latest sales update matters for investors Buckle (BKE) just released sales figures showing higher comparable store and total net sales for both the recent 5 week period and the 48 week year to date period, putting fresh attention on how its retail model is performing. See our latest analysis for Buckle. Buckle’s recent sales update lands after a mixed stretch for the stock, with a 1-day share price return of 2.48% contrasting with slightly negative 30 and 90 day share price...

Merck (NYSE:MRK) is reportedly in advanced talks to acquire Revolution Medicines in one of the largest biotech deals in recent years. The potential acquisition would expand Merck's oncology pipeline, with a focus on targeted cancer therapies. Merck is also a founding partner in Illumina's new AI driven pharmacogenomics initiative. Recent collaborations with ChemLex and Guardant Health point to a broader push into AI enabled drug discovery and precision oncology. For investors, this cluster...

Earlier in January 2026, Ocugen announced positive preliminary 12‑month Phase 2 ArMaDa data for OCU410 in geographic atrophy secondary to dry age‑related macular degeneration, showing reduced lesion growth and favorable safety across evaluated patients. An interesting highlight is that medium doses produced greater lesion growth reduction than high doses, and no serious OCU410‑related adverse events were reported in either Phase 1 or Phase 2 so far. Next, we’ll assess how this early OCU410...

Colgate-Palmolive (NYSE:CL) has started a multi-year collaboration with the WHO Foundation focused on global oral health. The partnership centers on funding programs that expand oral health education, integrate oral care into national health systems, and build public awareness. This move positions Colgate-Palmolive alongside a major global health institution with an emphasis on long term public health impact. For investors watching NYSE:CL, this development sits alongside a share price of...

What Kraft Heinz’s Recent Returns May Signal for Investors Kraft Heinz (KHC) has seen its share price under pressure recently, with negative returns over the past month, past 3 months, year to date, and past year, even as annual revenue and net income figures remain positive. See our latest analysis for Kraft Heinz. At a share price of $23.76, Kraft Heinz’s momentum looks muted, with a 30 day share price return of a 3.06% decline and a 1 year total shareholder return of a 14.58% loss,...